Treatment of infections caused by metronidazole-resistant Trichomonas vaginalis

Clinical Microbiology Reviews

Volumn 17, Issue 4, 2004, Pages 783-793

  Cudmore, Sarah L ^b   Delgaty, Kiera L ^b   Hayward McClelland, Shannon F ^b   Petrin, Dino P ^b   Garber, Gary E ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANISOMYCIN; ANTITRICHOMONAL AGENT; ARSONIC ACID DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; BERBERINE; CLOTRIMAZOLE; DISULFIRAM; FURAZOLIDONE; HAMYCIN; HYDRAZONE DERIVATIVE; METRONIDAZOLE; MISONIDAZOLE; NIFURATEL; NIMORAZOLE; NIRIDAZOLE; NITAZOXANIDE; NITROFURAN DERIVATIVE; NITROIMIDAZOLE DERIVATIVE; NITROPRUSSIDE SODIUM; ORNIDAZOLE; PAROMOMYCIN; SODIUM NITRITE; SPIROARSORANE DERIVATIVE; SULFIMIDAZOLE; TETRACYCLINE DERIVATIVE; THIADIAZINE DERIVATIVE; TINIDAZOLE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CELLULAR IMMUNODEFICIENCY; CONFUSION; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG TISSUE LEVEL; EOSINOPHILIA; GASTROINTESTINAL TOXICITY; HEADACHE; HEART PALPITATION; HUMAN; HYPERSENSITIVITY; IMMUNOSUPPRESSIVE TREATMENT; INSOMNIA; LEUKOPENIA; NAUSEA; PERIPHERAL NEUROPATHY; PNEUMOCYSTOSIS; POLYNEUROPATHY; RASH; REVIEW; SEXUALLY TRANSMITTED DISEASE; SIDE EFFECT; TASTE DISORDER; TRICHOMONAS VAGINALIS; TRICHOMONIASIS; VOMITING; XEROSTOMIA;

ANIMALS; ANTITRICHOMONAL AGENTS; DRUG RESISTANCE; FEMALE; HUMANS; METRONIDAZOLE; SEXUALLY TRANSMITTED DISEASES; TRICHOMONAS VAGINALIS; TRICHOMONAS VAGINITIS;

PROTOZOA; TRICHOMONAS VAGINALIS;

EID: 5644222543     PISSN: 08938512     EISSN: None     Source Type: Journal    
DOI: 10.1128/CMR.17.4.783-793.2004     Document Type: Review

References (130)

1. Abraham, M. C., M. Desjardins, L. G. Filion, and G. E. Garber. 1996. Inducible immunity to Trichomonas vaginalis in a mouse model of vaginal infection. Infect. Immun. 64:3571-3575.
2. Aburel, E., G. Zervos, V. Titea, and S. Pana. 1963. Immunological and therapeutic investigations in vaginal trichomoniasis. Rom. Med. Rev. 7:13-19.
3. Adugu, I. S., D. Nolder, D. S. Warhurst, and J. F. Rossignol. 2002. In vitro activity of nitazoxanide and related compounds against isolates of Giardia intestinalis, Entamoeba histolytica, and Trichomonas vaginalis. J. Antimicrob. Chemother. 49:103-111.
4. Ackers, J. P. 1990. Immunologic aspects of human trichomoniasis, p. 35-52. In B. M. Honigberg (ed.), Trichomonads parasitic in humans. Springer-Verlag, New York, N.Y.
5. Addis, M. A., P. Rappelli, A. M. P. de Andrade, F. M. Rita, M. M. Colombo, P. Cappuccinelli, and P. L. Fiori. 1999. Identification of Trichomonas vaginalis α-actinin as the most common immunogen recognized by the sera of women exposed to the parasite. J. Infect. Dis. 180:1727-1730.
6. Ahmed-Jushuf I., A. E. Murray, and J. McKeown. 1988. Managing trichomonal vaginitis refractory to conventional treatment with metronidazole. Genitourin. Med. 64:25-29.
7. Alcalde, E., L. Perez-Garcia, I. Dinares, G. H. Coombs, and J. Frigola. 1992. Synthesis and antitrichomonal activity of azinium (azolium) 4-nitrobenzimidazolate betaines and their derivatives. Eur. J. Med. Chem. 27:171-176.
8. Alderete, J. F. 1984. Enzyme linked immunosorbent assay for detecting antibody to Trichomonas vaginalis: use of whole cells and aqueous extract as antigen. Br. J. Vener. Dis. 60:164-170.
9. Alderete, J. F. 1988. Does lactobacillus vaccine for trichomoniasis, Solco-Trichovac, induce antibody reactive with Trichomonas vaginalis? Genitourin. Med. 64:118-123.
10. Alderete, J. F., and D. Provenzano. 1997. The vagina has reducing environment sufficient for activation of Trichomonas vaginalis cysteine proteinases. Genitourin. Med. 73:291-296.
11. Alper, M. M., B. N. Barwin, W. M. McLean, I. J. McGilveray, and S. Sved. 1985. Systemic absorption of metronidazole by the vaginal route. Obstet. Gynecol. 65:781-784.
12. Anorlu, R. L., A. F. Fagbenro-Beyioku, T. Fagorala, O. O. Abudu, and H. S. Galadanci. 2001. Prevalence of Trichomonas vaginalis in patients with vaginal discharge in Lagos, Nigeria. Niger. Postgrad. Med. J. 8:183-186.
13. Atienza, J., R. A. M. Diaz, A. G. Barrio, J. A. Escario, A. Herrero, C. Ochoa, and J. Rodriguez. 1992. Activity assays of thiadiazine derivatives on Trichomonas vaginalis and amastigote forms of Trypanosoma cruzi Chemotherapy 38:441-446.
14. Bouma, M. J. D. Snowdon, A. H. Fairlamb, and J. P. Ackers. 1998. Activity of disulfiram ((bis)diethylthiocarbamoyl)disulphide) and didiocarb (diethyldithiocarbamate) against metronidazole sensitive and resistant Trichomonas vaginalis and Tritrichomonas foetus. J. Antimicrob. Chemother. 42:817-820.
15. Cameron, D. E., and N. S. Padian. 1990. Sexual transmission of HIV and the epidemiology of other sexually transmitted diseases. AIDS 4(Suppl. 1):S99-S103.
16. Caro-Paton, T., A. Carvajal, I. M. Diego, L. H. Martin-Arias, A. A. Requejo, and E. R. Pinilla. 1997. Is metronidazole teratogenic? A meta-analysis. Br. J. Clin. Pharm. 44:179-182.
17. Chapman, A., R. Cammack, D. Linstead, and D. Lloyd. 1985. The generation of metronidazole radicals in hydrogenosomes isolated from Trichomonas vaginalis. J. Gen. Microbiol. 131:2141-2144.
18. Cobo, E. R., D. Cano, O. Rossetti, and C. M. Campero. 2002. Heifers immunized with whole-cell and membrane vaccines against Tritrichomonas foetus and naturally challenged with an infected bull. Vet. Parasitol. 109: 169-184.
19. Cogne, M., P. Brasseur, and J. J. Ballet. 1985. Detection and characterization of serum antitrichomonal antibodies in urogenital trichomoniasis. J. Clin. Microbiol. 21:588-592.
20. Conner, T. H., M. Stoeckel, J. Evrard, and M. S. Legator. 1977. The contribution of metronidazole and two metabolites to the mutagenic activity detected in the urine in treated humans and mice. Cancer Res. 37:629-633.
21. Corbeil, L. B. 1995. Use of an animal model of trichomoniasis as a basis for understanding this disease in women. Clin. Infect. Dis. 21:5158-5161.
22. Cosar, C., and L. Julou. 1959. Activity of 1-(2-hydroxyethyl)-2-methyl-5- nitroimidazole (8823 RP) against experimental Trichomonas vaginalis infection. Ann. Inst. Pasteur 96:238-241.
23. Cunningham, F. E., D. M. Kraus, L. Brubaker, and J. H. Fischer. 1994. Pharmacokinetics of intravaginal metronidazole gel. J. Clin. Pharmacol. 34:1060-1065.
24. Czeizel, A. E., and M. Rockenbauer. 1998. A population based case-control teratologic study of oral metronidazole treatment during pregnancy. Br. J. Obstet. Gynecol. 105:322-327.
25. Davis, B., D. D. Glover, and B. Larsen. 1984. Analysis of metronidazole penetration into vaginal fluid by reversed-phase high-performance liquid chromatography. Am. J. Obstet. Gynecol. 149:802-803.
26. Declerck, P. J., and C. J. De Ranter. 1986. In vitro reductive activation of nitroimidazoles. Biochem. Pharmacol. 35:59-61.
27. Demes, P., A. Gombosova, M. Valent, and A. Janoska. 1987. Factors of nonspecific immunity in human trichomoniasis. Acta Univ. Carol.-Biol. 30:337-342.
28. Dubini, F., L. Riviera, C. Cocuzza, and M. G. Bellotti. 1992. Antibacterial, antimycotic, and trichomonicidal activity of a new nitroimidazole (EU 11100). J. Chemother. 4:342-346.
29. Dunne, R. L., L. A. Dunne, P. Upcroft, P. J. O'Donoghue, and J. A. Upcroft. 2003. Drug resistance in the sexually transmitted parasitic protozoan Trichomonas vaginalis. Cell Res. 13:239-249.
30. Edwards, D. I., M. Dye, and H. Carne. 1973. The selective toxicity of antimicrobial nitroheterocyclic drugs. J. Gen. Microbiol. 76:135-145.
31. Edwards D. I., E. J. Thompson, J. Tomusange, and D. Hanson. 1979. Inactivation of metronidazole fay aerobic organisms. J. Antimicrob. Chemother. 5:315-316.
32. Edwards, D. I. 1980. Mechanisms of selective toxicity of metronidazole and other nitroimidazole drugs. Br. J. Vener. Dis. 56:285-290.
33. Edwards, D. I. 1993. Nitroimidazole drugs-action and resistance mechanisms. I. Mechanisms of action. J. Antimicrob. Chemother. 31:9-20.
34. Ellis, J. E., N. Yarlett, D. Cole, M. J. Humphreys, and D. Lloyd. 1994. Antioxidant defences in the microaerophilic protozoan Trichomonas vaginalis: comparison of metronidazole-resistant and sensitive strains. Microbiology 140:2489-2494.
35. Fouts, A. C., and S. J. Kraus. 1980. Trichomonas vaginalis: a re-evaluation of its clinical presentation and laboratory diagnosis. J. Infect. Dis. 141:137-143.
36. Garber, G. E., E. M. Proctor, and W. R. Bowie. 1986. Immunogenic proteins of Trichomonas vaginalis as demonstrated by the immunoblot technique. Infect. Immun. 51:250-253.
37. Garber, G. E., L. T. Lemchuk-Favel, and G. Rousseau. 1991. Effect of β-estradiol on production of the cell detaching factor of Trichomonas vaginalis. J. Clin. Microbiol. 29:1847-1849.
38. Gerbase, A. C., J. T. Rowley, D. H. Heymann, S. B. F Berkeley, and P. Piot. 1998. Global prevalence and incidence estimates of selected curable STDs. Sex. Transm. Dis. 74(Suppl. 1):S12-S16.
39. Gombosova, A., P. Demes, and M. Valent. 1986. Immunotherapeutic effect of the lactobacillus vaccine, SolcoTrichovac, in trichomoniasis is not mediated by antibodies cross reacting with Trichomonas vaginalis. Genitourin. Med. 62:107-110.
40. Goode, M. A., K. Grauer, and J. G. Gums. 1994. Infectious vaginitis. Selecting therapy and preventing recurrence. Postgrad. Med. 96:85-98.
41. Gupta, P. K., and J. K. Frost. 1990. Cytopathology and histopathology of the female genital tract in Trichomonas vaginalis infection, p. 274-290. In B. M. Honigberg (ed.) Trichomonads parasitic in humans. Springer-Verlag, New York, N.Y.
42. Hayward-McClelland, S. F., K. L. Delgaty, and G. E. Garber. 1999. Animal models of Trichomonas vaginalis infection with special emphasis on the intravaginal mouse model, p. 839-850. In O. Zak and M. Sande (ed.), Handbook of animal models of infection. Academic Press, Inc., New York, N.Y.
43. Heine, P., and J. A. MacGregor. 1993. Trichomonas vaginalis: a re-emerging pathogen. Clin. Obstet. Gynecol. 36:137-144.
44. Honigberg, B. M. 1987. Immunology of trichomonads, with emphasis on Trichomonas vaginalis: a review. Acta. Univ. Carol.-Biol. 30:321-336.
45. Houghton, G. W., J. Smith, P. S. Thorne, and R. Templeton. 1979. The pharmacokinetics of oral and intravenous metronidazole in man. Antimicrob. Chemother. 5:621-623.
46. Ingham H. R., C. J. Hall, P. R. Sisson, D. Tharagonnet, and J. B. Selkon. 1979. Inactivation of metronidazole by aerobic organisms. J. Antimicrob. Chemother. 5:734-735.
47. Ings, R. M., J. A. McFadzean, and W. E. Ormerod. 1974. The mode of action of metronidazole in Trichomonas vaginalis and other micro-organisms. Biochem. Pharmacol. 23:1421-1429.
48. Jensen, J. C., and R. Gugler. 1982. Single- and multiple-dose metronidazole kinetics. Clin. Pharmacol. Ther. 34:481-486.
49. Kane P. O., J. A. McFadzean, and S. Squires. 1961. Absorption and excretion of metronidazole. II. Studies on primary failures. Br. J. Vener. Dis. 37:276-277.
50. Kaneda, Y., M. Torii, T. Tanaka, and M. Aikawa. 1991. In vitro effects of berberine sulphate on the growth and structure of Entamoeba histolytica, Giardia lamblia, and Trichomonas vaginalis. Ann. Trop. Med. Parasitol. 85:417-425.
51. Kanna, M., and J. D. Sobel. 2003. Late recurrence of resistant Trichomonas vaginalis vaginitis: relapse or re-infection? Sex. Transm. Infect. 79:260-261.
52. Katiyar, S. K., and T. D. Edlind. 1991. Enhanced antiparasitic activity of lipophilic tetracyclines: role of uptake. Antimicrob. Agents Chemother. 35:2198-2202.
53. Katiyar, S. K., V. R. Gordon, G. L. McLaughlin, and T. D. Edlind. 1994. Antiprotozoal activities of benzimidazoles and correlations with β-tubulin sequence. Antimicrob. Agents Chemother. 38:2086-2090.
54. Knox, R. J., R. C. Knight, and D. I. Edwards. 1981. Misonidazole-induced thymidine release from DNA. Biochem. Pharmacol. 30:1925-1929.
55. Krieger, J. N., and M. F. Rein. 1982. Zinc sensitivities of Trichomonas vaginalis: in vitro studies and clinical implications. J. Infect. Dis. 146:341-345.
56. Krieger, J. N. 1984. Prostatitis syndromes: pathophysiology, differential diagnosis, and treatment. Sex. Transm. Dis. 11:100-112.
57. Krieger, J. N. 1990. Epidemiology and clinical manifestations of urogenital trichomoniasis in men, p. 235-245. In B. M. Honigberg (ed.), Trichomonads parasitic in humans. Springer-Verlag, New York, N.Y.
58. Kuberski, T. 1980. Trichomonas vaginalis associated with nongonococcal urethritis and prostatitis. Sex. Transm. Dis. 7:134-136.
59. Kulda, J., J. Tachezy, and A. Cerkasovova. 1993. In vitro induced anaerobic resistance to metronidazole in Trichomonas vaginalis. J. Eukaryot. Microbiol. 40:262-269.
60. Lafleur, M. V., E. J. Pluijmackers-Westmijze, and H. Loman. 1986. Effect of radiation-induced reduction of nitroimidazoles on biologically active DNA. Int. J. Radiat. Oncol. Biol. Phys. 12:1211-1214.
61. Laga, M., A. T. Manoka, M. Kivuvu, B. Malele, M. Tuliza, N. Nzila, J. B. Goeman, F. V. Batter, M. Alary, et al. 1993. Non-ulcerative sexually transmitted diseases as risk factors to HIV-1 transmission in women: results from a cohort study. AIDS 7:95-102.
62. Laga, M., M. Alary, N. Nzila, A. T. Manoka, M. Tuliza, F. Behets, J. S. Goeman, M. Louis, and P. Piot. 1994. Condom promotion, sexually transmitted disease treatment, and declining incidence of HIV-1 infection in female Zairian sex workers. Lancet 344:246-248.
63. Land, K. M., M. G. Delgadillo-Correa, J. Tachezy, S. Nanacova, C. L. Hseih, R. Sutak, and P. J. Johnson. 2004. Targeted gene replacement of a ferredoxin gene in Trichomonas vaginalis does not lead to metronidazole resistance. Mol. Microbiol. 51:115-120.
64. Landolfo, S., M. G. Martinotti, P. Martinetto, and G. Forni. 1980. Natural cell-mediated cytotoxicity against Trichomonas vaginalis in the mouse. J. Immun. 124:508-514.
65. Lau, A. H., N. P. Lam, S. C. Piscitelli, L. Wilkes, and L. H. Danziger. 1992. Clinical pharmocokinetics of metronidazole and other nitroimidazole anti-infectives. Clin. Pharmacokinet. 23:328-364.
66. Lehker, M. W., R. Arroyo, and J. F. Aldrete. 1991. The regulation by iron of the synthesis of adhesins and cytoadherence levels in the protozoan parasite Trichomonas vaginalis. J. Exp. Med. 171:2165-2170.
67. Lehker, M. W., and D. Sweeney. 1999. Trichomonad invasion of the mucous layer requires adhesins, mucinases, and motility. Sex. Transm. Infect. 75: 231-238.
68. Lewis, D. A., L. Habgood, R. White, K. F. Barker, and S. M. Murphy. 1997. Managing vaginal trichomoniasis resistant to high-dose metronidazole therapy. Int. J. STD AIDS. 8:780-784.
69. Lindmark, D. G., and M. Muller. 1976. Antitrichomonad action, mutagenicity, and reduction of metronidazole and other nitroimidazoles. Antimicrob. Agents Chemother. 10:476-482.
70. Lloyd, D., and B. Kristensen. 1985. Metronidazole inhibition of hydrogen production in vivo in drug-sensitive and resistant strains of Trichomonas vaginalis. J. Gen. Microbiol. 131:849-853.
71. Loiseau, P. M., L. Rekik, Y. Madaule, P. Gayral, and J. G. Wolf. 1993. Design, synthesis and biological study of antiparasitic spiroarsoranes. Arzneim.-Forsch./Drug Res. 43:1004-1009.
72. Lorenz, U., and H. Ruttgers. 1983. Clinical experience using Solco Trichovac in the treatment of trichomonas infections in women. Gynaekol. Rundsch. 23(Suppl.2):64-71.
73. Lossick, J. G. 1982. Treatment of Trichomonas vaginalis infections. Rev. Infect. Dis. 4(Suppl.):S801-S818.
74. Lossick, J. G., M. Muller, and T. E. Gorrell. 1986. In vitro drug susceptibility and doses of metronidazole required for cure in cases of refractory vaginal trichomoniasis. J. Infect. Dis. 153:948-955.
75. Lossick, J. G. 1990. Epidemiology of urogenital trichomoniasis. Therapy of urogenital trichomoniasis, p. 324-341. In B. M. Honigberg (ed.), Trichomonads parasitic in humans. Springer-Verlag, New York, N.Y.
76. Lossick, J. G. 1990. Treatment of sexually transmitted diseases. Rev. Infect. Dis. 12(Suppl.6):S665-S681.
77. Lossick, J. G., and H. L. Kent. 1991. Trichomoniasis: trends in diagnosis and management. Am. J. Obstet. Gynecol. 165:1217-1222.
78. Lushbaugh, W. B., J. D. Cleary, and R. W. Finley. 1995. Cytotoxicity of hamycin for Trichomonas vaginalis, HeLa and BHK-21. J. Antimicrob. Chemother. 36:795-802.
79. Macickova, T., M. Kettner, and K. Linck. 1990. In vivo effect of 2,4-dinitrophenyl-substituted sugar hydrazones and phenylosazone against Trichomonas vaginalis and Tritrichomonas foetus. Pharmazie 45:204-206.
80. Malagoli, M., T. Ross, A. Baggio, G. Zandomeneghi, A. Zanca, C. Casolari, and M. Castelli. 2002. In vitro study of chemotherapeutic activity of sulphimidazole on some sensitive and metronidazole resistant Trichomonas vaginalis strains. Pharmacol. Res. 46:469-472.
81. Malla, N., I. Gupta, C. Sokhey, R. Sehgal, N. K. Ganguly, and R. C. Mahajan. 1988. In vitro evaluation of metronidazole and tinidazole on strains of Trichomonas vaginalis. Indian J. Med. Microbiol. 6:297-301.
82. Mardh, P. A., and S. Colleen. 1975. Search for urogenital tract infections in patients with symptoms of prostatitis. Studies on aerobic and strictly anaerobic bacteria, mycoplasmas, fungi, trichomonads and viruses. Scand. J. Urol. Nephrol. 9:8-16
83. Mason, P. R. 1979. Serodiagnosis of Trichomonas vaginalis infection by the indirect fluorescent antibody test. J. Clin. Pathol. 32:1211-1215.
84. Mason, P. R., and B. A. Patterson. 1985. Proliferative response of human lymphocytes to secretory and cellular antigens of Trichomonas vaginalis. J. Parasitol. 71:265-268.
85. Mason, P. R., and L. Gwanzura. 1988. Mouse spleen cell responses to trichomonal antigens in experimental Trichomonas vaginalis infection. J. Parasitol. 74:93-97.
86. Mattila, J., P. T. Mannisto, R. Mantyla, S. Nykanen, and U. Lamminsivu. 1983. Comparative pharmacokinetics of metronidazole and tinidazole as influenced by administration route. Antimicrob. Agents Chemother. 23: 721-725.
87. McFadzean, J. A., I. M. Pugh, S. L. Squires, and J. P. F Whelan. 1969. Further observations on strain sensitivity of Trichomonas vaginalis to metronidazole. Br. J. Vener. Dis. 45:161-162.
88. McGrory, T., and G. E. Garber. 1992. Mouse intravaginal infection with Trichomonas vaginalis and role of Lactobacillus acidophilus in sustaining infection. Infect. Immun. 60:2375-2379.
89. Meysick, K., and G. E. Garber. 1995. Trichomonas vaginalis. Curr. Opin. Infect. Dis. 8:22-25.
90. Milovanovic, R., R. Grcic, and L. Stojkovic. 1983. Changes in the vaginal flora of trichomoniasis patients after vaccination with SolcoTrichovac. Gynaekol. Rundsch. 23(Suppl. 2):50-55.
91. Milovanovic, R., R. Grcic, and L. Stojkovic. 1983. Serological study with SolcoTrichovac, a vaccine against Trichomonas vaginalis infection in women. Gynaekol. Rundsch. 23(Suppl. 2):39-45.
92. Muller, M. 1986. Reductive activation of nitroimidazoles in anaerobic microorganisms. Biochem. Pharmacol. 35:37-41.
93. Muller M., J. F. Lossick, and T. E. Gorrell. 1988. In vitro susceptibility of Trichomonas vaginalis to metronidazole and treatment outcome in vaginal trichomoniasis. Sex. Transm. Dis. 15:17-24.
94. Muscara, M. N., J. Pedrazzoli, E. L. Miranda, J. G. Ferraz, E. Hofstatter, G Leite, A. F. Magalhaes, S. Leonardi, and G. DeNucci. 1995. Plasma hydroxymetronidazole/metronidazole ratio in patients with liver disease and in healthy volunteers. Br. J. Clin. Pharmacol. 40:477-480.
95. Mutwiri, G. K., and L. B. Corbeil. 1998. Genital and systemic immune responses in a murine model of Tritrichomonas foetus infection. J. Parasitol. 84:321-327.
96. Narcisi, E. M., and W. E. Secor. 1996. In vitro effect of tinidazole and furazolidone on metronidazole-resistant Trichomonas vaginalis. Antimicrob. Agents Chemother. 40:1121-1125.
97. Nix, D. E., R. Tyrrell, and M. Muller. 1995. Pharmacodynamics of metronidazole determined by a time-kill assay for Trichomonas vaginalis. Antimicrob. Agents Chemother. 39:1848-1852.
98. O'Brien, R. W., and J. G. Morris. 1971. The ferredoxin-dependent reduction of chloramphenicol by Clostridium acetobutylicum. J. Gen. Microbiol. 67:265-271.
99. Pavic, R., and L. Stojkovic. 1983. Vaccination with SolcoTrichovac. Gynaekol. Rundsch. 23(Suppl.2):27-38.
100. Perez-Reyes, E., B. Kalvanaraman, and R. P. Mason. 1980. The reductive metabolism of metronidazole and ronidazole by aerobic liver microsomes. Mol. Pharmacol. 17:239-244.
101. Petrin, D., K. Delgaty, R. Bhatt, and G. E. Garber. 1998. Clinical and microbiological aspects of Trichomonas vaginalis. Clin. Microbiol. Rev. 11:300-317.
102. Poppe, W. A. J. 2001. Nitroimidazole resistant vaginal trichomoniasis treated with paromomycin. Eur. J. Obstet. Gynecol. Reprod. Biol. 96:119-120.
103. Quon, D. V., C. E. d'Oliveira, and P. J. Johnson. 1992. Reduced transcription of the ferredoxin gene in metronidazole-resistant Trichomonas vaginalis. Proc. Natl. Acad. Sci. USA 89:4402-4406.
104. Ralph, E. D., J. T. Clarke, R. D. Libke, R. P. Luthy, and W. M. M. Kirby. 1974. Pharmacokinetics of metronidazole as determined by bioassay. Antimicrob. Agents Chemother. 6:691-696.
105. Ralph, E. D., and M. M. Kirby. 1975. Bioassay of metronidazole with either anaerobic of aerobic incubation. J. Infect. Dis. 132:587-591.
106. Rasoloson, D., E. Tomkova, R. Cammack, J. Kulda, and J. Tachezy. 2001. Metronidazole resistant strains of Trichomonas vaginalis display increased sensitivity to oxygen. Parasitology 123:45-56.
107. Rein, M. F., and T. A. Chapel. 1975. Trichomoniasis, candidiasis, and the minor venereal diseases. Clin. Obstet. Gynecol. 18:73-88.
108. Rein, M. F. 1990. Clinical manifestations of urogenital trichomoniasis in women, p. 225-234. In B. M. Honigberg (ed.), Trichomonads parasitic in humans. Springer-Verlag, New York, N.Y.
109. Rosa, F. W., C. Baum, and M. Shaw. 1987. Pregnancy outcomes after first-trimester vaginitis drug therapy. Obstet. Gynecol. 69:751-755.
110. Ryu, J. S., and D. Lloyd. 1995. Cell cytotoxicity of sodium nitrite, sodium nitroprusside and Roussin's black salt against Trichomonas vaginalis. FEMS Microbiol. Lett. 130:183-188.
111. Sears, S. D., and J. O'Hare. 1988. In vitro susceptibility of Trichomonas vaginalis to 50 antimicrobial agents. Antimicrob. Agents Chemother. 32: 144-146.
112. Shaio, M., and P. Lin. 1995. Influence of humoral immunity on leukotriene B4 production by neutrophils in response to Trichomonas vaginalis stimulation. Parasite Immunol. 17:127-133.
113. Sharma, P., N. Malla, I. Gupta, N. K. Ganguly, and R. C. Mahajan. 1991. Anti-trichomonad IgA antibodies in trichomoniasis before and after treatment. Folia Microbiol. 36:302-304.
114. Sibau, L., D. Bebb, E. M. Proctor, and W. R. Bowie. 1987. Enzyme-linked immunosorbent assay for the diagnosis of trichomoniasis in women. Sex. Transm. Dis. 14:216-220.
115. Sorvillo, F., and P. Kerndt. 1998. Trichomonas vaginalis and amplification of HIV-1 transmission. Lancet 351:213-214.
116. Stambaugh, J. E., L. G. Feo, and R. W. Manthei. 1967. Isolation and identification of the major urinary metabolite of metronidazole. Life Sci. 6:1811-1819.
117. Stambaugh, J. E., L. G. Feo, and R. W. Manthei. 1968. The isolation and identification of the urinary oxidative metabolites of metronidazole in man. J. Pharmacol. Exp. Ther. 161:373-381.
118. Street, D. A., D. Taylor-Robinson, J. P. Ackers, N. F. Hanna, and A. McMillan. 1982. Evaluation of an enzyme-linked immunosorbent assay for the detection of antibody to Trichomonas vaginalis in sera and vaginal secretions. Br. Vener. Dis. 58:330-333.
119. Su, K. E. 1982. Antibody to Trichomonas vaginalis in human cervicovaginal secretions. Infect. Immun. 37:852-857.
120. Tachezy, J., J. Kulda, and E. Tomkova. 1993. Aerobic resistance of Trichomonas vaginalis to metronidazole induced in vitro. Parasitology 106: 31-37.
121. Ti, T. Y., H. S. Lee, and Y. M. Khoo. 1996. Disposition of intravenous metronidazole in Asian surgical patients. Antimicrob. Agents Chemother. 40:2248-2251.
122. Trani, A., C. Dallanoce, G. Panzone, F. Ripamonti, B. P. Goldstein, and R. Ciabatti. 1997. Semisynthetic derivatives of purpuromycin as potential topical agents for vaginal infections. J. Med. Chem. 40:967-971.
123. Upcroft, P., and J. A. Upcroft. 2001. Drug targets and mechanisms of resistance in the anaerobic protozoa. Clin. Microbiol. Rev. 14:150-164.
124. Vidakovic, M., C. R. Crossnoe, C. Neidre, K. Kim, K. L. Krause, and J. P. Germanas. 2003. Reactivity of reduced [2Fe-2S] ferredoxins parallels host susceptibility to nitroimidazoles. Antimicrob. Agents Chemother. 47:302-308.
125. Voolmann, T., and P. Borehan. 1993. Metronidazole resistant Trichomonas vaginalis in Brisbane. Med. J. Aust. 159:140.
126. Wilmott, F., J. Say, and A. Hookam. 1983. Zinc and recalcitrant trichomoniasis. Lancet i:1053.
127. Wolner-Hanssen, P., J. N. Krieger, C. E. Stevens, N. B. Kiviat, L. Koutsky, Critchlow, T. DeRouen, S. Hillier, and K. K. Holmes. 1989. Clinical manifestations of vaginal trichomoniasis. JAMA 261:571-576.
128. Yano, A., F. Aosai, K. Yui, S. Kojima, and T. Kawana. 1983. Antigen-specific proliferation response of peripheral blood lymphocytes to Trichomonas vaginalis antigen in patients with Trichomonas vaginitis. J. Clin. Microbiol. 17:175-180.
129. Yarlett, N., C. C. Rowlands, N. C. Yarlett, J. C. Evans, and D. Lloyd. 1987. Reduction of niridazole by metronidazole resistant and susceptible strains of Trichomonas vaginalis. Parasitology 94:93-99.
130. Ziomko, J., and J. E. Kuczynska. 1994. Trichomonacidal activity of newly synthesized derivatives of benzoizothiazolinone (BIT) in vitro. Wiad. Parazytol. 40:59-64.